Creo Medical Group PLC
LSE:CREO
Creo Medical Group PLC
Cost of Revenue
Creo Medical Group PLC
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Creo Medical Group PLC
LSE:CREO
|
Cost of Revenue
-£14m
|
CAGR 3-Years
-1 081%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Smith & Nephew PLC
LSE:SN
|
Cost of Revenue
-$1.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
LivaNova PLC
NASDAQ:LIVN
|
Cost of Revenue
-$380.5m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-30%
|
|
LumiraDx Ltd
NASDAQ:LMDX
|
Cost of Revenue
-$193.5m
|
CAGR 3-Years
-138%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Cost of Revenue
-£28.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
Angle PLC
LSE:AGL
|
Cost of Revenue
-£723k
|
CAGR 3-Years
-53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Creo Medical Group PLC's Cost of Revenue?
Cost of Revenue
-14m
GBP
Based on the financial report for Dec 31, 2022, Creo Medical Group PLC's Cost of Revenue amounts to -14m GBP.
What is Creo Medical Group PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-1 081%
Over the last year, the Cost of Revenue growth was -3%. The average annual Cost of Revenue growth rates for Creo Medical Group PLC have been -1 081% over the past three years .